Oragenics Management

Management criteria checks 2/4

Oragenics' CEO is Janet Huffman, appointed in Mar 2023, has a tenure of 1.92 years. total yearly compensation is $365.40K, comprised of 57% salary and 43% bonuses, including company stock and options. directly owns 0.12% of the company’s shares, worth $4.63K. The average tenure of the management team and the board of directors is 1 years and 14.3 years respectively.

Key information

Janet Huffman

Chief executive officer

US$365.4k

Total compensation

CEO salary percentage	57.0%
CEO tenure	1.9yrs
CEO ownership	0.1%
Management average tenure	less than a year
Board average tenure	14.3yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Janet Huffman's remuneration changed compared to Oragenics's earnings?
Date	Total Compensation	Salary	Company Earnings
Sep 30 2024	n/a	n/a	-US$20m
Jun 30 2024	n/a	n/a	-US$20m
Mar 31 2024	n/a	n/a	-US$20m
Dec 31 2023	US$365k	US$208k	-US$21m

Compensation vs Market: Janet's total compensation ($USD365.40K) is below average for companies of similar size in the US market ($USD640.24K).

Compensation vs Earnings: Insufficient data to compare Janet's compensation with company performance.

CEO

Janet Huffman (51 yo)

1.9yrs

Tenure

US$365,396

Compensation

Ms. Janet Huffman is Interim Chief Executive Officer of Oragenics, Inc. since January 16, 2025 and served as its Interim Principal Executive Officer and President since December 16, 2024 until 2025 and ser...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Charles Pope	Executive Chairman	14.7yrs	US$196.75k	0.21% $ 7.9k
Janet Huffman	Interim CEO & CFO	1.9yrs	US$365.40k	0.12% $ 4.6k
James Kelly	Chief Medical Officer & Member of Scientific Advisor	less than a year	no data	no data
William Peacock	Chief Clinical Officer	less than a year	no data	no data
Christine Farrell	Vice President of Finance	no data	no data	no data

1.0yrs

Average Tenure

64yo

Average Age

Experienced Management: OGEN's management team is not considered experienced ( 1 years average tenure), which suggests a new team.

Board Members

Name	Position	Tenure	Compensation	Ownership
Charles Pope	Executive Chairman	14.7yrs	US$196.75k	0.21% $ 7.9k
James Kelly	Chief Medical Officer & Member of Scientific Advisor	1.1yrs	no data	no data
John Gandolfo	Independent Director	1.3yrs	US$25.13k	0% $ 0
Frederick Telling	Independent Director	14.7yrs	US$156.75k	0.28% $ 10.7k
Alan Dunton	Independent Director	13.8yrs	US$140.50k	0.21% $ 7.9k
Robert Koski	Independent Director	15.7yrs	US$134.25k	0.23% $ 8.6k

14.3yrs

Average Tenure

70yo

Average Age

Experienced Board: OGEN's board of directors are seasoned and experienced ( 14.3 years average tenure).

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2025/02/03 08:42
End of Day Share Price	2025/01/31 00:00
Earnings	2024/09/30
Annual Earnings	2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Oragenics, Inc. is covered by 6 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Edward Woo	Ascendiant Capital Markets LLC
Theodore O'Neill	Ascendiant Capital Markets LLC
Keith Markey	Griffin Securities

Oragenics Management

Management criteria checks 2/4

Key information

Recent management updates

Oragenics, Inc Appoints Janet Huffman as Interim Chief Executive Officer

Oragenics, Inc. Appoints William “Frank” Peacock MD as Chief Clinical Officer

Oragenics Appoints James Kelly MD as Chief Medical Officer, to Lead Phase II Clinical Trials for Treating Concussion

Oragenics, Inc. Announces Leadership Transition

Oragenics, Inc., Annual General Meeting, Dec 14, 2023

Oragenics Announces Directorate Appointments

Recent updates

Oragenics, Inc Appoints Janet Huffman as Interim Chief Executive Officer

Oragenics, Inc. has filed a Follow-on Equity Offering.

Oragenics, Inc. has filed a Follow-on Equity Offering in the amount of $10 million.

Oragenics, Inc. Plans to Initiate Phase II Clinical Trials

Oragenics Inc. Successfully Completes Key FDA-Recognized Study for ONP-002

Oragenics, Inc. has completed a Follow-on Equity Offering in the amount of $4.453593 million.

Oragenics, Inc. has filed a Follow-on Equity Offering in the amount of $4.453593 million.

Oragenics Inc. Completes Spray Dry Drug Manufacturing and Intranasal Device Filling in Anticipation of Phase IIa Clinical Trial in Concussed Patients

Oragenics, Inc. has filed a Follow-on Equity Offering.

Oragenics, Inc. Shows Concussion Drug, ONP-002, Designed for Acute Field-Delivery Stable Across a Wide Temperature Range

New major risk - Financial position

First half 2024 earnings released: US$1.21 loss per share (vs US$2.92 loss in 1H 2023)

Oragenics Inc. Announces Concussion Drug, ONP-002, Successfully Clears FDA-Required Cardiotoxicity Testing

Oragenics Improves Intranasal Drug Formulation for Treating Concussed Patients

Oragenics, Inc. has completed a Follow-on Equity Offering.

Oragenics, Inc. has filed a Follow-on Equity Offering.

Oragenics Announces NYSE American Acceptance of Plan of Compliance

Oragenics, Inc. Appoints William “Frank” Peacock MD as Chief Clinical Officer

Oragenics, Inc. Prepares Intranasal Pharmaceutical, ONP-002, for Phase II Concussion Trial

First quarter 2024 earnings released: US$0.70 loss per share (vs US$1.41 loss in 1Q 2023)

Full year 2023 earnings released: US$9.18 loss per share (vs US$7.11 loss in FY 2022)

Oragenics Appoints James Kelly MD as Chief Medical Officer, to Lead Phase II Clinical Trials for Treating Concussion

Oragenics, Inc. Prepares Drug for Phase II Clinical Trials to Treat Concussion

Oragenics, Inc. has completed a Follow-on Equity Offering in the amount of $2.1 million.

Oragenics, Inc. has filed a Follow-on Equity Offering.

Oragenics, Inc. Announces Leadership Transition

Oragenics, Inc. Prepares for Phase II Clinical Trials to Treat Concussion

New major risk - Share price stability

Oragenics, Inc. has completed a Follow-on Equity Offering in the amount of $5 million.

Oragenics, Inc. has filed a Follow-on Equity Offering.

Oragenics, Inc. (NYSEAM:OGEN) completed the acquisition of Assets related to proprietary neurological drug therapies and technologies of Odyssey Health, Inc.

Third quarter 2023 earnings released: US$0.85 loss per share (vs US$1.99 loss in 3Q 2022)

Oragenics, Inc., Annual General Meeting, Dec 14, 2023

Oragenics Announces Directorate Appointments

Oragenics, Inc. (NYSEAM:OGEN) entered into an Asset Purchase Agreement to acquire Assets related to proprietary neurological drug therapies and technologies of Odyssey Health, Inc.

Second quarter 2023 earnings released: US$1.51 loss per share (vs US$1.85 loss in 2Q 2022)

Oragenics, Inc. announced that it has received $0.85 million in funding

Oragenics, Inc. Announces the Award of Grant from CQDM for the Collaborative Development of a Variant-Agnostic COVID-19 Protein Subunit Vaccine Candidate

Insufficient new directors

Oragenics, Inc. Regains Compliance with NYSE American

Oragenics, Inc. Reports Favorable Toxicology Results for Its Covid-19 Intranasal Vaccine Candidate

Oragenics, Inc. Receives NYSE American Notice Regarding Compliance with Section 1003(f)(v)

Oragenics, Inc. Announces Board Changes

Oragenics, Inc. Appoints Kimberly Murphy as Secretary and Treasurer

Oragenics, Inc. Announces Resignation of Michael Sullivan as Chief Financial Officer, Effective from December 14, 2022

Price target increased to US$2.25

Oragenics, Inc., Annual General Meeting, Dec 16, 2022

Oragenics Announces Favorable Preliminary Toxicology Data for Intranasal COVID-19 Vaccine Candidate

Price target increased to US$2.25

Oragenics, Inc. Appoints Kimberly M. Murphy as Chief Executive Officer

Oragenics Announces Publication of Positive Data for Its NT-Cov2-1 Intranasal Covid-19 Vaccine Candidate in Scientific Reports

Price target decreased to US$2.25

CEO Compensation Analysis

CEO

Tenure

Compensation

Leadership Team

Average Tenure

Average Age

Board Members

Average Tenure

Average Age

Company Analysis and Financial Data Status

Data Sources

Analysis Model and Snowflake

Industry and Sector Metrics

Analyst Sources